Aligos Therapeutics Operating Margin vs. Net Income
| ALGS Stock | USD 7.10 0.16 2.31% |
Aligos Therapeutics Operating Profit Margin |
|
For Aligos Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Aligos Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Aligos Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Aligos Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Aligos Therapeutics over time as well as its relative position and ranking within its peers.
Check out Trending Equities. Is there potential for Biotechnology market expansion? Will Aligos introduce new products? Factors like these will boost the valuation of Aligos Therapeutics. If investors know Aligos will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Aligos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (13.54) | Revenue Per Share | Quarterly Revenue Growth (0.42) | Return On Assets | Return On Equity |
Investors evaluate Aligos Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Aligos Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Aligos Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Aligos Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aligos Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Aligos Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Aligos Therapeutics Net Income vs. Operating Margin Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Aligos Therapeutics's current stock value. Our valuation model uses many indicators to compare Aligos Therapeutics value to that of its competitors to determine the firm's financial worth. Aligos Therapeutics is rated fourth in operating margin category among its peers. It is rated below average in net income category among its peers . At this time, Aligos Therapeutics' Operating Profit Margin is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Aligos Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Aligos Net Income vs. Operating Margin
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Aligos Therapeutics |
| = | (38.27) % |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Aligos Therapeutics |
| = | (131.21 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Aligos Net Income Comparison
Aligos Therapeutics is currently under evaluation in net income category among its peers.
Aligos Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Aligos Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Aligos Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Aligos Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Aligos Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 518.6 K | 544.6 K | |
| Net Interest Income | 5.1 M | 5.3 M | |
| Interest Income | 1.4 M | 1 M | |
| Operating Income | -80.2 M | -84.3 M | |
| Net Loss | -118.1 M | -124 M | |
| Income Before Tax | -117.8 M | -123.7 M | |
| Total Other Income Expense Net | -37.6 M | -35.7 M | |
| Net Loss | -86.4 M | -90.8 M | |
| Net Loss | -118.1 M | -124 M | |
| Income Tax Expense | 380.6 K | 212 K | |
| Non Operating Income Net Other | -65.5 K | -68.8 K | |
| Change To Netincome | 16.9 M | 9.7 M | |
| Net Loss | (24.09) | (22.88) | |
| Income Quality | 0.55 | 0.60 | |
| Net Income Per E B T | 0.90 | 0.80 |
Aligos Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Aligos Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Aligos Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Aligos Therapeutics' important profitability drivers and their relationship over time.
Aligos Therapeutics Earnings Estimation Breakdown
The calculation of Aligos Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Aligos Therapeutics is estimated to be -1.896975 with the future projection ranging from a low of -2.377875 to a high of -0.6075. Please be aware that this consensus of annual earnings estimates for Aligos Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-2.38 Lowest | Expected EPS | -0.61 Highest |
Aligos Therapeutics Earnings Projection Consensus
Suppose the current estimates of Aligos Therapeutics' value are higher than the current market price of the Aligos Therapeutics stock. In this case, investors may conclude that Aligos Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Aligos Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 5 | 8.22% | -3.04 | -1.896975 | -13.54 |
Aligos Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Aligos Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Aligos Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Aligos Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Aligos Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Aligos Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Aligos Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Aligos Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Aligos Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-11-06 | 2025-09-30 | -0.25 | -3.04 | -2.79 | 1116 | ||
2025-08-06 | 2025-06-30 | -0.24 | -1.53 | -1.29 | 537 | ||
2025-05-05 | 2025-03-31 | -3.1533 | -2.1133 | 1.04 | 32 | ||
2025-03-10 | 2024-12-31 | -3.67 | -13.1 | -9.43 | 256 | ||
2024-11-06 | 2024-09-30 | -2.16 | -3.07 | -0.91 | 42 | ||
2024-08-06 | 2024-06-30 | -0.16 | 0.03 | 0.19 | 118 | ||
2024-05-07 | 2024-03-31 | -0.19 | -0.22 | -0.03 | 15 | ||
2024-03-12 | 2023-12-31 | -0.27 | -0.22 | 0.05 | 18 | ||
2023-11-02 | 2023-09-30 | -0.47 | -0.41 | 0.06 | 12 | ||
2023-08-03 | 2023-06-30 | -0.49 | -0.43 | 0.06 | 12 | ||
2023-05-04 | 2023-03-31 | -0.48 | -0.53 | -0.05 | 10 | ||
2023-03-09 | 2022-12-31 | -0.47 | -0.51 | -0.04 | 8 | ||
2022-11-02 | 2022-09-30 | -0.58 | -0.44 | 0.14 | 24 | ||
2022-08-04 | 2022-06-30 | -0.67 | -0.47 | 0.2 | 29 | ||
2022-05-04 | 2022-03-31 | -0.73 | -0.84 | -0.11 | 15 | ||
2022-03-10 | 2021-12-31 | -0.83 | -0.89 | -0.06 | 7 | ||
2021-11-04 | 2021-09-30 | -0.81 | -0.78 | 0.03 | 3 | ||
2021-08-05 | 2021-06-30 | -0.81 | -0.79 | 0.02 | 2 | ||
2021-05-10 | 2021-03-31 | -0.9 | -0.74 | 0.16 | 17 | ||
2021-03-23 | 2020-12-31 | -0.82 | -1.09 | -0.27 | 32 | ||
2020-11-25 | 2020-09-30 | -0.78 | -11.0 | -10.22 | 1310 | ||
2020-09-25 | 2020-06-30 | 0 | -1.42 | -1.42 | 0 |
Use Aligos Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aligos Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aligos Therapeutics will appreciate offsetting losses from the drop in the long position's value.Aligos Therapeutics Pair Trading
Aligos Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Aligos Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aligos Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aligos Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aligos Therapeutics to buy it.
The correlation of Aligos Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aligos Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aligos Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aligos Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Aligos Therapeutics position
In addition to having Aligos Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Monster Funds Thematic Idea Now
Monster Funds
Solid funds with above average long term performance indicators based on Macroaxis rating system. The Monster Funds theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Monster Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.